Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.
Artificial intelligence in drug development
From rapid candidate selection, to fewer clinical trials and faster market approval, artificial intelligence approaches are helping to accelerate and improve the efficiency of drug development, whilst significantly reducing costs. Here we present a number of companies working in the field.
Insilico: linking target discovery and generative chemistry AI platforms for a drug discovery breakthrough
With its unique target discovery platforms, PandaOmics and Chemistry42, AI company Insilico is transforming the world of research and development.
Auransa’s AI-driven prediction of drug candidates and corresponding patient responders increases the chances of clinical trial success.
Lemonex is opening a new era of safe and highly effective immunotherapy and RNA therapy with a pipeline of candidates based on DegradaBALL, its proprietary porous nanoparticle drug-delivery platform
Chemiverse provides a quicker route to ‘the best target, the best chemical,’ according to the Korean biotech Pharos iBio. With its first AI-based drug currently undergoing clinical trials, the company is demonstrating the broad value AI can provide from discovery to clinical development.
Combining cell sorting technology with artificial intelligence, Japan-based ThinkCyte aims to discover novel high-value therapeutic cells, new functional genes, and novel drug candidates for itself and its partners worldwide.
Better data for better insights and improved outcomes—Molecular Health has built one of the largest, deepest and fully curated digital platforms for biomedicine in the world. The company’s ‘Dataome’ provides the foundation for actionable insights for stakeholders across the healthcare ecosystem.
Deep Quartet, a drug discovery platform developed by INTAGE Healthcare and the Institute for Theoretical Medicine (ITM) uses AI technologies to design new lead compound structures based on pharmacophore models.
Sparse Modeling delivers fast, energy efficient and explainable AI solutions for cutting-edge medical applications
Japanese AI specialist HACARUS Inc. is successfully utilizing its proprietary Sparse Modeling AI technology in joint projects including phenotype drug discovery, medical imaging and ECG monitors for human and veterinary applications.
KaiPharm’s KMAP platform combines drug-induced transcriptome profiles and artificial intelligence to accelerate drug development and drug repositioning.
Paige, a global leader in artificial intelligence–based diagnostic software, has built a flexible and scalable digital pathology platform that streamlines tissue analysis and affords opportunities for novel biomarker discovery. The company has a flexible partnership model designed to maximize outcomes for collaborators and patients.
How Daiichi Sankyo and LPIXEL unlocked the power of phenotypic screening.
Augmented intelligence at the service of personalised medicine: how artificial intelligence is accelerating drug discovery and development
By harnessing patient and disease data, multi-omics and scientific literature, the fast-growing, AI company My Intelligent Machines (MIMs) is breaking new ground with software solutions that accelerate the identification of drug targets and biomarkers.